Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Buy” by Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received an average rating of “Buy” from the six ratings firms that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $25.20.

ATXS has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Friday, September 27th. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. TD Cowen assumed coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They set a “buy” rating and a $35.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, Oppenheimer increased their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th.

Institutional Trading of Astria Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers grew its position in Astria Therapeutics by 4.1% in the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock worth $595,000 after buying an additional 2,556 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Astria Therapeutics by 135.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 2,861 shares in the last quarter. Quest Partners LLC grew its holdings in shares of Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares during the last quarter. American International Group Inc. raised its position in shares of Astria Therapeutics by 49.4% during the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock worth $346,000 after purchasing an additional 8,122 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Astria Therapeutics by 6.9% during the second quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock valued at $1,266,000 after purchasing an additional 8,965 shares during the last quarter. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Stock Up 1.3 %

Astria Therapeutics stock opened at $11.32 on Wednesday. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90. The firm has a market capitalization of $638.67 million, a price-to-earnings ratio of -4.92 and a beta of 0.71. The firm has a 50-day moving average price of $11.54 and a two-hundred day moving average price of $10.50.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Research analysts expect that Astria Therapeutics will post -1.68 earnings per share for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.